跳至主要内容

Organic Chemistry Synthesis of Medicilon

 As a leading provider of chemical synthesis services, we provide reference compounds, intermediates, drug candidates, impurities, metabolites, and other small molecule chemicals from milligram to kilogram level (including GMP quality).

The chemistry synthesis service comes with weekly updates, final reports and ordered amounts of the compound under strict confidentiality. Final reports contain sufficient information for you to readily repeat the chemistry in house if needed.

Medicilon has synthesized 10,000 individual compounds from gram kilogram quantities, and many compounds are synthesized with more than ten synthetic steps. The overall synthesis success rate is over 95%.

chemical synthesis service

Chemical Synthesis Service

We utilize medical chemistry and computational chemistry to design and synthesize drug-like templates and libraries of compounds to increase our client’s compound collections. The annual capacity of library production is more than 100,000 compounds.

We have successfully supplied one client 6kgs of product with 8 synthetic steps within a very short period, including reaction optimization.

As a trailblazing in synthetic chemistry service supported by a strong analytical chemistry team, Medicilon is committed to deliver the highest quality and value to our clients measured by productivity, speed and proactive communication.

In this typically full-time-equivalent (FTE) arrangement, the client sends us the target structures, and we perform the route design and deliver the molecules. Whether the compounds are designed for the discovery of a novel drug, or a crop protection product, or a performance chemical, a close interaction with timely communications between the clients and our teams is the key to ensure that the right molecules are synthesized and the irrelevant molecules are dropped. Our dedicated logistics and compound management teams ensure expedient delivery of the compounds to the right location and in the right format for evaluations. We work with our clients to streamline the workflow to maximize productivity and to shorten the design-synthesis-evaluation cycle time.

Medicilon can undertake the synthesis of special reagents, intermediates and molecular fragments, preparation of standard products, synthesis design and preparation of impurities or metabolites, synthesis of stable isotope internal standards and synthesis of tritiated compounds.

Custom Synthesis

  • From Milligram to Kilogram Level High Quality Product Preparation

  • Special Reagent, Intermediate and Template Preparation

  • API or Related Material Preparation

  • Impurity and Metabolite Study

  • Analytical Support

  • Related Reports

Well-designed and well-validated analytical methodology is critical data integrity and central to our approach. We work closely with clients to ensure that our methodology will yield accurate results. Meanwhile, our precise quality systems ensure that all the facilities, equipment, methods, practices, records, and control will be tightly complied with our regulations, study protocols, and standard operating procedures.

Contact Us 

Email : marketing@medicilon.com
Tel : +86 021 58591500

Tips:  Above is part of organic chemistry synthesis.  You can also CONTACT US with any question or enquiry you may have. We will be happy to discuss your needs in detail and design an appropriate plan of action.

评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati